Wan Mohamed Wan M I, Sayuti Suzila C, Draman Nani
Department of Internal Medicine, School of Medical Sciences, Universiti Sains Malaysia, Health Campus, Kubang Kerian, Kelantan, Malaysia.
Department of Family Medicine, School of Medical Sciences, Universiti Sains Malaysia, Health Campus, Kubang Kerian, Malaysia.
J Taibah Univ Med Sci. 2018 Jul 18;13(5):432-437. doi: 10.1016/j.jtumed.2018.06.004. eCollection 2018 Oct.
The aim of this study was to determine the incidence of hypothyroidism and its associated factors within one-year post radioactive iodine (RAI) therapy.
A retrospective study was conducted among patients with hyperthyroidism who received RAI therapy at Nuclear Medicine Clinic, Hospital Universiti Sains Malaysia (HUSM), Kelantan. Data regarding patients' demographics, gender, aetiology of hyperthyroidism, presence of autoantibodies, dose of RAI used and usage of antithyroid drug post RAI therapy were included in the analysis.
Of a total of 167 screened patients, 137 subjects were eligible for this study. The incidence of hypothyroidism within one year of RAI therapy was 32.9%. Women were found to be less likely to develop hypothyroidism post RAI therapy (adjusted odds ratio, 0.406; 95% confidence interval: 0.181-0.908; = 0.028). The usage of antithyroid drug post RAI was significantly associated with a lower incidence of hypothyroidism post RAI therapy (adjusted odds ratio, 0.188; 95% confidence interval: 0.081-0.438; <0.001).
This study showed a high incidence of hypothyroidism within one-year post RAI therapy. Gender and usage of antithyroid drug post RAI therapy are significantly associated with the development of hypothyroidism.
本研究旨在确定放射性碘(RAI)治疗后一年内甲状腺功能减退症的发生率及其相关因素。
对在马来西亚理科大学医院(HUSM)吉兰丹核医学诊所接受RAI治疗的甲状腺功能亢进症患者进行了一项回顾性研究。分析纳入了患者的人口统计学数据、性别、甲状腺功能亢进症的病因、自身抗体的存在情况、使用的RAI剂量以及RAI治疗后抗甲状腺药物的使用情况。
在总共167名筛查患者中,137名受试者符合本研究条件。RAI治疗后一年内甲状腺功能减退症的发生率为32.9%。发现女性在RAI治疗后发生甲状腺功能减退症的可能性较小(调整后的优势比,0.406;95%置信区间:0.181 - 0.908;P = 0.028)。RAI治疗后使用抗甲状腺药物与RAI治疗后甲状腺功能减退症的较低发生率显著相关(调整后的优势比,0.188;95%置信区间:0.081 - 0.438;P < 0.001)。
本研究显示RAI治疗后一年内甲状腺功能减退症的发生率较高。性别和RAI治疗后抗甲状腺药物的使用与甲状腺功能减退症的发生显著相关。